Gwendolyn Binder sold $215k of CABA
See Remarks at Cabaletta Bio, Inc.. 11,000 shares at an average of $19.59, traded Jan 19, 2024, filed Jan 19, 2024.
Score components
- +15RoleOfficer
- +12Trade size$215k at market
- +10Share of holdings soldSold 35% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-005888, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 19, 2024 | MOption exercise Common Stock10b5-1 | +11,000 | $1.01 | $11k | 31,000 | Jan 19, 2024 |
| Jan 19, 2024 | SOpen-market sale Common Stock10b5-1 | -10,300 | $19.54 | $201k | 20,700 | Jan 19, 2024 |
| Jan 19, 2024 | SOpen-market sale Common Stock10b5-1 | -700 | $20.33 | $14k | 20,000 | Jan 19, 2024 |
| Jan 19, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -11,000 | $0.00 | $0 | 100,756 | Jan 19, 2024 |
Related signals
Other insiders at Cabaletta Bio, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | Cabaletta Bio, Inc. | Gwendolyn Binder President, Science & Tech. | $25k 11,312 shares | +57% | |
| 40Moderate | Cabaletta Bio, Inc. | Catherine Bollard director | $9,982 4,405 shares | +441% | |
| 38Weak | Cabaletta Bio, Inc. | Michael Gerard General Counsel | $15k 6,600 shares | - | |
| 38Weak | Cabaletta Bio, Inc. | Mark Simon director | $25k 11,061 shares | +8% | |
| 50Moderate | Cabaletta Bio, Inc. | Steven Nichtberger President & CEO | $101k 45,000 shares | +5% | |
| 45Moderate | Cabaletta Bio, Inc. | Steve Gavel Chief Commercial Officer | $50k 22,170 shares | - | |
| 45Moderate | Cabaletta Bio, Inc. | Shawn Tomasello director | $50k 22,725 shares | - | |
| 38Weak | Cabaletta Bio, Inc. | David J. Chang Chief Medical Officer | $20k 8,800 shares | - | |
| 3Weak | Cabaletta Bio, Inc. | Gwendolyn Binder See Remarks | $241k 11,000 shares | -35% | |
| 2Weak | Cabaletta Bio, Inc. | Gwendolyn Binder See Remarks | $196k 11,000 shares | -35% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.